Iressa and Radiotherapy in the treatment of the locally advanced inoperable squamous cell carcinoma of the head and neck

Study identifier:1839IL/0070

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A 2 part phase 2 trial to evaluate ZD1839 (Iressa™) & radiotherapy in patients w/locally advanced inoperable squamous cell carcinoma of the head & neck

Medical condition

head and neck cancer

Phase

Phase 2

Healthy volunteers

Study drug

Iressa (Gefitinib)

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Jul 2003

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Milano, Italy

Location

Research Site

Napoli, Italy

Location

Research Site

Aviano, Italy

Location

Research Site

Ragusa, Italy

Location

Research Site

Palermo, Italy

Location

Research Site

Azienda, Italy

Arms	Assigned Interventions

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1517&filename=CSR-1839IL0-0070.pdf
Download
CSR-1839IL-0070.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Italy Study Information

+39 02 98011

Investigators

Principal Investigator

AstraZeneca Italy Medical Director

AstraZeneca

Iressa and Radiotherapy in the treatment of the locally advanced inoperable squamous cell carcinoma of the head and neck

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1517&filename=CSR-1839IL0-0070.pdf

CSR-1839IL-0070.pdf

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator